Parties
Company
Brookfield Asset Management
Company
Grifols
Brookfield Asset Management is considering a €7 billion (approximately $10 billion) bid to acquire Grifols, a Spanish pharmaceutical company specializing in blood plasma-based products.
Brookfield is contemplating a public tender offer at €10.5 per share, which is below Grifols' recent market closing price of €11.125.
Grifols has experienced a 30 percent decline in market value since January 2024.
Deal Type
Merger & AcquisitionIndustry
HealthcareTransaction
$ 10,390,520,000Deal Status
ActiveClosing Date